Compounded Semaglutide in 2026: What Changed and What's Still Available

Compounded semaglutide is a custom-prepared version of the GLP-1 medication typically found in brand-name drugs like Wegovy and Ozempic, made by specialized pharmacies when FDA-approved versions are in short supply or cost-prohibitive. Throughout 2024 and 2025, compounding semaglutide became a lifeline for thousands of patients who couldn't access or afford brand-name options—but 2026 brought seismic shifts that left many scrambling.

If you've been using compounded semaglutide or you're considering it, you're probably wondering what the hell happened. The rules changed fast. Some pharmacies pulled products overnight, while others kept compounding under different regulations. It's messy, honestly.

What Is Compounded Semaglutide?

Compounded semaglutide is semaglutide that's prepared by a compounding pharmacy rather than a pharmaceutical manufacturer. These pharmacies take active pharmaceutical ingredients (APIs) and create custom formulations—different doses, different delivery methods, sometimes combined with other compounds like B12 or L-carnitine.

Why would anyone want this instead of just getting Wegovy or Ozempic? Money, mostly. Brand-name semaglutide can run $1,000+ per month without insurance. Compounded versions? Often $200-400. That's not pocket change for most folks.

But there's a catch—actually, several catches. Compounded medications don't go through the same FDA approval process as brand-name drugs. They're legal under specific circumstances, mainly when there's a drug shortage or when a patient needs a customized dose that isn't commercially available. The quality can vary wildly between pharmacies, and that's where things get dicey.

Some compounding pharmacies are meticulous, following strict quality controls and testing every batch. Others? Let's just say the standards aren't always what you'd hope for. We've seen reports of contaminated batches, incorrect dosing, and products that degraded faster than expected because of improper storage or formulation issues.

The FDA Shortage and Compounding: How It Started

The whole compounded semaglutide boom started because Novo Nordisk couldn't make enough Wegovy and Ozempic to meet demand. We're talking about a shortage that officially began in March 2022 and dragged on for years.

When the FDA declares a drug shortage, compounding pharmacies are legally allowed to step in and fill the gap. That's exactly what happened. Hundreds of compounding operations—some legitimate 503B outsourcing facilities, others small 503A pharmacies—started making their own semaglutide formulations.

Patients loved it. Doctors liked having options for folks who couldn't afford brand names. Online telehealth companies built entire business models around prescribing compounded GLP-1s. Companies like Hims & Hers, Ro, and dozens of smaller players scaled up fast, offering monthly subscriptions that included telemedicine visits and shipped medication.

But Novo Nordisk wasn't thrilled. They argued that many compounding pharmacies were making semaglutide products that went beyond what the shortage rules technically allowed—essentially creating commercial-scale operations instead of patient-specific prescriptions.

The FDA walked a tightrope. On one hand, they needed to protect patient access during a genuine shortage. On the other, they couldn't ignore quality concerns and the pharmaceutical industry's complaints about what they saw as unregulated competition.

What Changed in 2026: Shortage Resolution and Legal Battles

Here's where everything went sideways. In late 2025, Novo Nordisk ramped up production significantly. By early 2026, the FDA started evaluating whether the shortage was truly resolved.

On February 28, 2026, the FDA removed semaglutide from the official drug shortage list. That single action changed everything for compounding pharmacies overnight—or it was supposed to.

Under federal law, once a drug is no longer in shortage, compounding pharmacies can't make copies of it unless they meet very specific criteria. Patients would need documented reasons why they couldn't use the FDA-approved versions—like allergies to inactive ingredients or needing a dose not commercially available.

Except it didn't quite work out that cleanly. Several things happened simultaneously that created chaos:

First, advocacy groups and patients filed complaints arguing the shortage wasn't actually resolved. They pointed to continued intermittent supply issues and the fact that lower doses of Wegovy were still periodically unavailable. The FDA faced pressure to reconsider.

Second, the telehealth companies that'd built their businesses on compounded semaglutide weren't about to just shut down. Some continued operating, arguing their pharmacies were using the 503A exception for patient-specific needs. Others pivoted to different GLP-1s that were still in shortage, like tirzepatide.

Third—and this is huge—Novo Nordisk filed lawsuits. They went after specific compounding pharmacies and the trade associations representing them, arguing that continued compounding of semaglutide was illegal and harmful to patients. The legal battles are still ongoing as of this writing.

What's actually available now depends on which state you're in, which pharmacy you work with, and honestly, how aggressive your provider is about documenting medical necessity. It's a patchwork system, which is frustrating for everyone involved.

503A vs 503B Compounding Pharmacies: Key Differences

Not all compounding pharmacies are created equal. There are two main types under federal law, and understanding the difference matters if you're trying to source compounded semaglutide.

503A pharmacies are traditional compounding pharmacies. They're regulated primarily by state boards of pharmacy. These facilities can only make medications based on individual patient prescriptions—they can't manufacture in bulk or stockpile products ahead of demand. They're supposed to have a direct relationship between patient, prescriber, and pharmacy.

In theory, 503A pharmacies offer more flexibility for customization. Your doctor can request a specific dose, a different salt form, or combinations with other compounds. The quality control requirements are less stringent than what 503B facilities face, though reputable 503A pharmacies still test their products.

503B outsourcing facilities are a different beast entirely. They're regulated by the FDA and can manufacture larger batches without individual patient prescriptions. They register with the FDA, undergo inspections, and must follow current Good Manufacturing Practices (cGMP)—the same standards pharmaceutical companies follow.

503B facilities can distribute to healthcare providers and systems, not just individual patients. They're allowed to make products in advance of receiving orders. The trade-off? Much stricter oversight, regular FDA inspections, and mandatory adverse event reporting.

Which is safer? Generally, 503B facilities have better quality controls because of FDA oversight. But a well-run 503A pharmacy can absolutely produce high-quality medications. The problem is there's more variability in the 503A world.

After the 2026 shortage resolution, 503B facilities faced tighter restrictions on continuing to make semaglutide. Many stopped entirely to avoid legal risk. Some 503A pharmacies continued under the medical necessity exception, but it's a gray area that makes both pharmacies and prescribers nervous.

Cost Comparison: Brand vs Compounded Semaglutide

Let's talk dollars and cents, because that's what drives most of this conversation anyway.

Brand-name semaglutide—Wegovy for weight loss or Ozempic for diabetes—lists at around $1,200-1,400 per month without insurance. With good insurance coverage, you might pay $25-50 per month. Without coverage or if your insurance denies it? You're looking at the full sticker price or slightly discounted cash prices around $900-1,000.

Novo Nordisk introduced a savings program in 2025 that reduced costs for some patients, but eligibility requirements meant many folks still couldn't access it. If you make too much money to qualify for assistance but not enough to casually drop $1,000+ monthly on medication, you're stuck in a brutal middle ground.

Compounded semaglutide typically ran $200-400 per month through telehealth platforms during the shortage years. Some pharmacies charged as low as $150 for lower doses. Others, especially those marketing premium "pharmaceutical-grade" formulations, charged $500-600. Still significantly cheaper than brand-name options for most patients.

The cost difference came from several factors. Compounding pharmacies don't have the research, development, and marketing costs that Novo Nordisk amortizes into their pricing. They're buying APIs from suppliers (albeit at varying quality levels) and preparing them in relatively simple formulations. There's no nationwide advertising campaign or sales force.

After the 2026 changes, compounded semaglutide prices shifted. Some pharmacies raised prices, arguing increased regulatory requirements and legal risks justified it. Others lowered prices to stay competitive as more patients returned to brand-name options when insurance coverage improved.

What we're seeing now is a bifurcated market. Patients with good insurance coverage tend to use Wegovy or Ozempic. Those paying cash—whether because of insurance denials, high deductibles, or no coverage—still seek out compounded options when they can find pharmacies willing to fill prescriptions.

Is the savings worth the potential quality risks? That's a personal calculation everyone has to make. Some patients figure the risk is minimal and the savings are life-changing. Others prioritize the consistency and FDA oversight of brand-name products. There's no universally right answer, which is frustrating but honest.

Quality Concerns: What to Verify Before Using Compounded GLP-1s

Here's the thing nobody wants to admit but everyone needs to hear: compounded semaglutide quality varies massively, and there've been some genuinely concerning incidents.

In 2024 and 2025, we saw reports of patients experiencing unusual side effects, products that seemed less effective than expected, and even a few cases of contamination. The FDA issued warning letters to several compounding pharmacies for quality violations. One pharmacy in Nevada was shut down after investigators found bacterial contamination in multiple products, including semaglutide formulations.

The problem is that not all APIs are created equal. Some compounding pharmacies source their semaglutide from reputable manufacturers who provide certificates of analysis and purity testing. Others buy from cheaper suppliers with questionable quality controls. There's no easy way for patients to know the difference just by looking at their prescription vial.

So what should you verify before using compounded semaglutide? Here's what actually matters:

Check if the pharmacy is 503A or 503B registered. 503B facilities are listed on the FDA's website. You can verify their registration status and see if they've received warning letters or inspections with issues. 503A pharmacies are harder to check, but your state board of pharmacy should have licensing records.

Ask about sterility testing. Semaglutide for injection needs to be sterile. Period. Reputable compounding pharmacies test every batch for sterility and endotoxins. Ask your pharmacy if they do batch testing and if they can provide you with test results for your specific lot number. If they can't or won't, that's a red flag.

Look for third-party testing. Some pharmacies send samples to independent labs for potency verification. This isn't required by law for 503A pharmacies, so if a pharmacy does it voluntarily, that's a good sign. They should be able to show you certificates of analysis.

Verify the API source. Ask where the pharmacy gets their semaglutide active ingredient. Legitimate suppliers include companies registered with the FDA. If the pharmacy won't tell you or seems evasive, walk away.

Check storage and shipping practices. Semaglutide needs to be refrigerated. If your medication arrives warm or the pharmacy ships it without cold packs and temperature monitoring, that's a problem. Degraded semaglutide might not hurt you, but it won't work properly either.

Read reviews and check complaint records. State boards of pharmacy maintain complaint records. Check if the pharmacy has a history of issues. Online reviews can be hit-or-miss, but patterns matter—lots of reports about side effects or ineffectiveness warrant caution.

Honestly? If you're working with a telehealth company that won't tell you which pharmacy they use or won't provide detailed quality information, that's sketchy. Reputable operations are transparent about their weight management protocols and sourcing.

The Novo Nordisk Legal Challenge

Novo Nordisk didn't just sit quietly while compounding pharmacies chipped away at their market share. They came out swinging legally, and it's created a complicated landscape for everyone involved.

The company's argument goes like this: compounded versions of semaglutide are potentially dangerous because they haven't undergone the rigorous testing that Wegovy and Ozempic did. They claim some pharmacies are using salt forms of semaglutide that differ from the FDA-approved versions, which means they're essentially different drugs that haven't been proven safe or effective.

Specifically, Novo Nordisk argued that many compounders were using semaglutide sodium rather than semaglutide base, which is what's in the brand-name products. The company contended this wasn't just making a generic copy—it was making a different chemical entity that hadn't been studied in clinical trials.

In late 2025, Novo Nordisk filed suit against the Outsourcing Facilities Association and several individual compounding pharmacies. They also petitioned the FDA to issue stronger enforcement guidance. The company pulled out all the stops: full-page newspaper ads warning patients about compounded GLP-1 risks, PR campaigns featuring doctors discussing safety concerns, and lobbying efforts in state legislatures.

The compounding industry fought back. Trade associations argued that compounding has always been legal for patient-specific needs, shortage or not. They pointed out that thousands of patients had used compounded semaglutide safely and that restricting access would harm people who genuinely needed more affordable options.

Patient advocacy groups joined in, organizing letter-writing campaigns and social media pushes. Some accused Novo Nordisk of prioritizing profits over patient access—the company made $13+ billion on semaglutide products in 2025 alone.

As of mid-2026, the legal battles are still unfolding. Several courts have issued preliminary rulings, but nothing's been definitively settled. The FDA hasn't issued comprehensive new guidance, probably because they're waiting to see how the litigation shakes out.

What this means practically: there's enormous uncertainty. Some compounding pharmacies have stopped making semaglutide entirely to avoid legal risk. Others continue but require extensive documentation of medical necessity. A few are gambling that the courts will ultimately side with the compounding industry.

Patients and prescribers are caught in the middle, trying to navigate shifting rules and incomplete information. It sucks, frankly.

Sublingual and Oral Compounded Options

Here's an interesting wrinkle: not all compounded semaglutide comes in injectable form. Some compounding pharmacies started offering sublingual (under the tongue) and oral versions, arguing these represented genuinely different formulations that fell outside Novo Nordisk's patents and the shortage restrictions.

The sublingual version typically comes as a dissolvable tablet or liquid that you hold under your tongue for several minutes. The idea is that semaglutide absorbs through the mucous membranes in your mouth, bypassing the digestive system.

Does it work? The data is... limited. Semaglutide is a large peptide molecule, and generally speaking, large peptides don't absorb well through oral mucosa without penetration enhancers or special formulation techniques. Some patients report success with sublingual compounded semaglutide, but there haven't been rigorous clinical trials to establish bioavailability or effectiveness.

Oral semaglutide is even trickier. Novo Nordisk has an FDA-approved oral version called Rybelsus, but it uses a proprietary absorption enhancer called SNAC to protect the semaglutide from stomach acid and help it absorb through the intestinal wall. That technology is patented.

Compounded oral semaglutide—without SNAC or similar enhancers—probably doesn't work well. Your stomach acid would break down most of the peptide before it could absorb. Some compounders claim they use alternative absorption enhancers, but without clinical data, it's hard to know if these formulations deliver therapeutic levels.

Why would anyone choose these routes over injection? Needle phobia is real. Some patients just hate injections and are willing to try alternatives even if the effectiveness is questionable. Others believe the sublingual route might offer more stable blood levels without the weekly peaks and troughs of injections.

My take? If you're considering sublingual or oral compounded semaglutide, ask hard questions about bioavailability data. If the pharmacy can't provide evidence that their formulation actually delivers adequate drug levels, you're probably wasting money. The injectable form has decades of research behind it. Alternative routes are experimental at best.

What Patients Should Ask Their Provider

If you're thinking about compounded semaglutide—or if you're already using it and wondering what to do post-2026—here are the questions you should actually ask your doctor or prescriber:

"Is brand-name semaglutide available and covered by my insurance now?" With the shortage resolved, check whether Wegovy or Ozempic is accessible to you. Insurance coverage has expanded as availability improved. You might qualify now even if you didn't before.

"What's the source and quality testing for the compounded version you're prescribing?" Your provider should know which pharmacy they're working with and what quality standards that pharmacy maintains. If they can't answer this, that's concerning.

"Am I legally eligible for compounded semaglutide now that the shortage is resolved?" Honest providers will explain the medical necessity requirements and whether your situation genuinely qualifies. Sketchy ones will just say yes without documentation.

"What happens if the pharmacy stops making this product?" Have a backup plan. Know whether you'd transition to brand-name or switch to a different GLP-1 medication entirely. Don't get caught without options.

"How do we monitor for quality issues or adverse effects?" Establish clear follow-up protocols. Regular check-ins, blood work if appropriate, and a plan for what to do if the medication seems less effective than expected or causes unusual side effects.

"What's the price difference between compounded and brand-name for my specific situation?" Get concrete numbers for your insurance coverage, cash prices, and any patient assistance programs you might qualify for. Make an informed financial decision.

"Are you prescribing the same salt form that's in the FDA-approved versions?" This matters because of the Novo Nordisk legal arguments. Semaglutide base vs. semaglutide sodium—ask which one you're getting and whether there's clinical data supporting its use.

Good providers won't be defensive about these questions. They'll appreciate that you're being thoughtful about your health and treatment choices. If a prescriber gets annoyed or evasive, consider finding someone else. This is your heart health and metabolic wellness we're talking about—you deserve clear answers.

Frequently Asked Questions About Compounded Semaglutide

Is compounded semaglutide legal in 2026?

Yes, but with restrictions. After the FDA removed semaglutide from the shortage list in February 2026, compounding pharmacies can only legally prepare it for patients with documented medical necessity—like allergies to inactive ingredients in brand-name versions or needing doses not commercially available. The legality is being challenged in courts, creating uncertainty.

How much does compounded semaglutide cost compared to Wegovy or Ozempic?

Compounded semaglutide typically costs $200-500 per month depending on the pharmacy and dose. Brand-name Wegovy or Ozempic lists at $1,200-1,400 monthly without insurance. With insurance coverage, brand-name options might cost $25-100 per month, potentially making them cheaper than compounded versions for insured patients.

Can I trust the quality of compounded semaglutide?

Quality varies significantly. 503B outsourcing facilities with FDA oversight generally have better quality controls than 503A pharmacies, which are state-regulated. Ask about sterility testing, API sourcing, third-party verification, and whether the pharmacy provides certificates of analysis. Some compounded products have been found contaminated or improperly formulated.

What's the difference between semaglutide base and semaglutide sodium?

Semaglutide base is the form used in FDA-approved Wegovy and Ozempic. Semaglutide sodium is a salt form used by many compounding pharmacies. Novo Nordisk argues these are different chemical entities requiring separate clinical trials. Some pharmacists contend they're bioequivalent. The debate is ongoing in legal proceedings.

Will my doctor prescribe compounded semaglutide now that the shortage is over?

It depends. Some providers continue prescribing compounded semaglutide for patients with documented medical necessity or financial hardship. Others have stopped entirely due to legal uncertainty or concerns about quality control. Many telehealth companies that previously specialized in compounded GLP-1s have shifted their practices or pivoted to other medications still in shortage.

Does sublingual semaglutide work as well as injections?

Probably not. There's no rigorous clinical data showing sublingual semaglutide achieves adequate bioavailability. Semaglutide is a large peptide that doesn't typically absorb well through oral mucosa without special formulation technology. Some patients report success, but without controlled trials, it's unclear whether sublingual forms deliver therapeutic levels consistently.

Can I switch from brand-name to compounded semaglutide or vice versa?

Yes, but work with your provider to manage the transition. You'll want to account for potential potency differences—compounded versions might be stronger or weaker than expected. Monitor your response carefully during the switch, adjust dosing if needed, and watch for side effects that might differ between formulations.

What should I do if my compounding pharmacy stops making semaglutide?

Have a backup plan ready. Talk to your provider about transitioning to brand-name Wegovy or Ozempic, switching to a different GLP-1 like tirzepatide (if available), or finding another compounding pharmacy still making semaglutide. Don't wait until your supply runs out—these transitions take time to arrange, especially if insurance approvals are needed.

Are there any advantages to compounded semaglutide over brand-name versions?

Cost is the main advantage—sometimes $800-1,000 less per month than brand-name options for cash-paying patients. Some compounders offer custom doses between the standard commercial strengths, which might benefit patients who need fine-tuned dosing. A few pharmacies combine semaglutide with B12 or other compounds, though the benefit of combinations isn't well-established.

How do I verify my compounding pharmacy is legitimate?

Check if 503B facilities are registered on the FDA's outsourcing facility list. For 503A pharmacies, verify licensing through your state board of pharmacy. Look for pharmacies that provide sterility testing results, certificates of analysis, and transparent information about API sourcing. Accreditation from organizations like PCAB (Pharmacy Compounding Accreditation Board) is a positive indicator, though not required.

What are the risks of using compounded semaglutide?

Potential risks include contaminated or non-sterile products, incorrect potency leading to under-dosing or over-dosing, products that degrade faster than expected, and formulations using different salt forms that haven't been clinically studied. There's also legal risk if pharmacies are forced to stop compounding due to litigation or regulatory changes, potentially disrupting your treatment.

Can I get compounded semaglutide if I don't have a medical necessity?

Legally, no—not anymore. After the shortage resolution, compounding pharmacies are only supposed to make semaglutide for patients who can't use FDA-approved versions due to documented medical reasons. In practice, some pharmacies and prescribers interpret "medical necessity" broadly to include cost barriers, but this is a gray area that might not hold up under legal scrutiny.

Will insurance cover compounded semaglutide?

Rarely. Most insurance plans don't cover compounded medications when FDA-approved alternatives are available. A few plans might cover compounded semaglutide with prior authorization demonstrating medical necessity, but you'd need documented allergies or other specific contraindications to brand-name versions. Most patients pay cash for compounded options.

What's the shelf life of compounded semaglutide compared to brand-name?

Brand-name Wegovy and Ozempic have well-established shelf lives—typically 24 months refrigerated when unopened. Compounded semaglutide stability depends on the formulation and pharmacy practices. Some pharmacies assign 30-90 day beyond-use dates. Others claim longer stability but may not have data to support it. Always check the beyond-use date on your compounded prescription and store it properly refrigerated.

Should I choose a 503A or 503B pharmacy for compounded semaglutide?

503B facilities generally offer better quality assurance due to FDA oversight, mandatory testing, and cGMP requirements. However, many 503B facilities stopped making semaglutide after the 2026 shortage resolution due to legal risk. 503A pharmacies continue operating under medical necessity exceptions but have more variable quality. If you have access to a reputable 503B facility, that's probably the safer choice—but verify they're still compounding semaglutide first.

Moving Forward: What to Expect

The compounded semaglutide landscape isn't going to stabilize anytime soon. Legal proceedings will probably drag into 2027 or beyond. The FDA might issue clearer guidance, or they might continue punting on definitive rules to avoid political backlash from either the pharmaceutical industry or patient advocates.

What we're likely to see is continued fragmentation. Some states might pass laws explicitly protecting compounding pharmacies' right to prepare semaglutide for patient-specific needs. Others might align more closely with FDA restrictions or even impose additional limitations.

Telehealth companies will keep adapting. Some have already shifted focus to tirzepatide (Mounjaro/Zepbound), which remained on shortage lists longer. Others are developing proprietary formulations or focusing on medications where brand-name costs are prohibitive regardless of shortage status.

For patients, the takeaway is simple: stay informed, ask questions, and don't assume your current access will continue indefinitely. Whether you're using compounded semaglutide now or considering it, have contingency plans. Know what brand-name options cost with your insurance. Understand the legal landscape in your state. Work with providers who are transparent about sourcing and quality.

The weight loss medication space is evolving rapidly, with new GLP-1 agonists and combination therapies in development. Compounded semaglutide served a genuine need during a multi-year shortage, giving thousands of patients access to treatment they couldn't otherwise afford. Whether it remains a viable option long-term depends on regulatory decisions, court rulings, and market forces that are still playing out.

Check your testing regularly if you're on any GLP-1 medication, compounded or not. Monitor metabolic markers, kidney function, and overall health. These are powerful medications with real effects—they deserve respect and careful medical oversight regardless of where they're made.

And if you're exploring options for longevity or metabolic optimization beyond GLP-1s, remember that peptides are just one tool in a much larger toolkit. Compounded semaglutide might be right for you, or it might not be. The important thing is making informed choices based on current evidence, quality standards, and your individual health situation.